Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jun;85(2):367–375. doi: 10.1111/j.1476-5381.1985.tb08870.x

Different responsiveness of prostaglandin D2-sensitive systems to prostaglandin D2 and its analogues.

S Narumiya, N Toda
PMCID: PMC1916609  PMID: 2992661

Abstract

Prostaglandin D2 (PGD2) and six PGD2 analogues were used to classify responsiveness of several PGD2-sensitive systems. The analogues used were 9 beta-PGD2, 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin (BW245C), 17-phenyl-18,19,20-trinor-PGD2 (17-phenyl-PGD2), PGD2 amide, PGD2 N-monomethylamide and 11-keto-15 alpha-hydroxy-delta 5,9,12-prostenoic acid (9-deoxy-delta 9,12-PGD2). The PGD2-sensitive systems examined were human platelets, rat peritoneal mast cells, rabbit transverse stomach strip, guinea-pig tracheal ring chain and helical strip of the dog cerebral artery. PGD2, 9 beta-PGD2 and BW245C inhibited the aggregation of human platelets, increased adenosine 3'5'-cyclic monophosphate (cyclic AMP) in rat mast cells and relaxed the rabbit stomach strip. The rank order of potency was BW245C greater than PGD2 greater than 9 beta-PGD2. PGD2 amide and PGD2 N-monomethylamide were inactive in the former two systems but elicited relaxant activity on the rabbit stomach strip. 17-Phenyl-PGD2 was virtually inactive in the above three systems. PGD2 and 17-phenyl-PGD2 contracted the guinea-pig tracheal ring chain and the helical strip of dog cerebral arteries with almost equal potency. 9 beta-PGD2 and BW245C antagonized competitively the contractile action of PGD2. PGD2 amide and PGD2 N-monomethylamide showed weak agonistic actions in the tracheal preparation. 9-Deoxy-delta 9,12-PGD2, showing stronger growth inhibition than PGD2 on cultured tumour cells, was inactive in human platelets, rat mast cells and guinea-pig trachea, and elicited contractile response in the rabbit stomach strip. These results indicate the presence of three groups of PGD2-sensitive systems that respond differently to PGD2 and its analogues.

Full text

PDF
367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  2. Bundy G. L., Morton D. R., Peterson D. C., Nishizawa E. E., Miller W. L. Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues. J Med Chem. 1983 Jun;26(6):790–799. doi: 10.1021/jm00360a003. [DOI] [PubMed] [Google Scholar]
  3. DULBECCO R., VOGT M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med. 1954 Feb;99(2):167–182. doi: 10.1084/jem.99.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feigen L. P., Chapnick B. M. Evidence for separate PGD2 and PGF2 alpha receptors in the canine mesenteric vascular bed. Prostaglandins. 1979 Aug;18(2):221–233. doi: 10.1016/0090-6980(79)90107-2. [DOI] [PubMed] [Google Scholar]
  5. Feinstein M. B., Egan J. J., Opas E. E. Reversal of thrombin-induced myosin phosphorylation and the assembly of cytoskeletal structures in platelets by the adenylate cyclase stimulants prostaglandin D2 and forskolin. J Biol Chem. 1983 Jan 25;258(2):1260–1267. [PubMed] [Google Scholar]
  6. Flower R. J., Harvey E. A., Kingston W. P. Inflammatory effects of prostaglandin D2 in rat and human skin. Br J Pharmacol. 1976 Feb;56(2):229–233. doi: 10.1111/j.1476-5381.1976.tb07446.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fukushima M., Kato T., Ota K., Arai Y., Narumiya S., Hayaishi O. 9-deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities. Biochem Biophys Res Commun. 1982 Dec 15;109(3):626–633. doi: 10.1016/0006-291x(82)91986-6. [DOI] [PubMed] [Google Scholar]
  8. Fukushima M., Kato T., Ueda R., Ota K., Narumiya S., Hayaishi O. Prostaglandin D2, a potential antineoplastic agent. Biochem Biophys Res Commun. 1982 Apr 14;105(3):956–964. doi: 10.1016/0006-291x(82)91063-4. [DOI] [PubMed] [Google Scholar]
  9. Hamberg M., Hedqvist P., Strandberg K., Svensson J., Samuelsson B. Prostaglandin endoperoxides IV. Effects on smooth muscle. Life Sci. 1975 Feb 1;16(3):451–462. doi: 10.1016/0024-3205(75)90266-0. [DOI] [PubMed] [Google Scholar]
  10. Holgate S. T., Lewis R. A., Maguire J. F., Roberts L. J., 2nd, Oates J. A., Austen K. F. Effects of prostaglandin D2 on rat serosal mast cells: discordance between immunologic mediator release and cyclic AMP levels. J Immunol. 1980 Sep;125(3):1367–1373. [PubMed] [Google Scholar]
  11. Honma M., Satoh T., Takezawa J., Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem Med. 1977 Dec;18(3):257–273. doi: 10.1016/0006-2944(77)90060-6. [DOI] [PubMed] [Google Scholar]
  12. Ikai K., Ogorochi T., Narumiya S. Prostaglandin D2 and prostaglandin D synthetase in mast cell deficient mice. Prostaglandins. 1984 Jun;27(6):877–885. doi: 10.1016/s0090-6980(84)80007-6. [DOI] [PubMed] [Google Scholar]
  13. Jones R. L. Definition of prostaglandin-sensitive arterial constrictor systems. Acta Biol Med Ger. 1978;37(5-6):837–844. [PubMed] [Google Scholar]
  14. Jones R. L., Peesapati V., Wilson N. H. Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br J Pharmacol. 1982 Jul;76(3):423–438. doi: 10.1111/j.1476-5381.1982.tb09236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kikawa Y., Narumiya S., Fukushima M., Wakatsuka H., Hayaishi O. 9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1317–1321. doi: 10.1073/pnas.81.5.1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mills D. C., Macfarlane D. E. Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb Res. 1974 Sep;5(3):401–412. doi: 10.1016/0049-3848(74)90176-5. [DOI] [PubMed] [Google Scholar]
  17. Nugteren D. H., Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta. 1973 Dec 20;326(3):448–461. doi: 10.1016/0005-2760(73)90145-8. [DOI] [PubMed] [Google Scholar]
  18. Schafer A. I., Cooper B., O'Hara D., Handin R. I. Identification of platelet receptors for prostaglandin I2 and D2. J Biol Chem. 1979 Apr 25;254(8):2914–2917. [PubMed] [Google Scholar]
  19. Schneider M. W., Drazen J. M. Comparative in vitro effects of arachidonic acid metabolites on tracheal spirals and parenchymal strips. Am Rev Respir Dis. 1980 May;121(5):835–842. doi: 10.1164/arrd.1980.121.5.835. [DOI] [PubMed] [Google Scholar]
  20. Seamon K. B., Padgett W., Daly J. W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3363–3367. doi: 10.1073/pnas.78.6.3363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Siegl A. M., Smith J. B., Silver M. J. Specific binding sites for prostaglandin D2 on human platelets. Biochem Biophys Res Commun. 1979 Sep 12;90(1):291–296. doi: 10.1016/0006-291x(79)91623-1. [DOI] [PubMed] [Google Scholar]
  22. Soter N. A., Lewis R. A., Corey E. J., Austen K. F. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983 Feb;80(2):115–119. doi: 10.1111/1523-1747.ep12531738. [DOI] [PubMed] [Google Scholar]
  23. Toda N. Different responsiveness of a variety of isolated dog arteries to prostaglandin D2. Prostaglandins. 1982 Jan;23(1):99–112. doi: 10.1016/0090-6980(82)90026-0. [DOI] [PubMed] [Google Scholar]
  24. Toda N. Mechanism of action of carbocyclic thromboxane A2 and its interaction with prostaglandin I2 and verapamil in isolated arteries. Circ Res. 1982 Dec;51(6):675–682. doi: 10.1161/01.res.51.6.675. [DOI] [PubMed] [Google Scholar]
  25. Town M. H., Casals-Stenzel J., Schillinger E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins. 1983 Jan;25(1):13–28. doi: 10.1016/0090-6980(83)90131-4. [DOI] [PubMed] [Google Scholar]
  26. Ueno R., Ishikawa Y., Nakayama T., Hayaishi O. Prostaglandin D2 induces sleep when microinjected into the preoptic area of conscious rats. Biochem Biophys Res Commun. 1982 Nov 30;109(2):576–582. doi: 10.1016/0006-291x(82)91760-0. [DOI] [PubMed] [Google Scholar]
  27. Ueno R., Narumiya S., Ogorochi T., Nakayama T., Ishikawa Y., Hayaishi O. Role of prostaglandin D2 in the hypothermia of rats caused by bacterial lipopolysaccharide. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6093–6097. doi: 10.1073/pnas.79.19.6093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  29. Whittle B. J., Moncada S., Vane J. R. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373–388. doi: 10.1016/0090-6980(78)90216-2. [DOI] [PubMed] [Google Scholar]
  30. Whittle B. J., Mugridge K. G., Moncada S. Use of the rabbit transverse stomach-strip to identify and assay prostacyclin, PGA2, PGD2 and other prostaglandins. Eur J Pharmacol. 1979 Jan 1;53(2):167–172. doi: 10.1016/0014-2999(79)90162-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES